Clinical outcomes after treatment for NDM-producing Klebsiella pneumoniae infection after kidney transplantation
10.3760/cma.j.cn421203-20220505-00097-1
- VernacularTitle:肾移植术后产NDM型金属β-内酰胺酶CRKP感染治疗的效果研究
- Author:
Xiao LI
1
;
Jiangwei ZHANG
;
Xiaohui TIAN
;
Hang YAN
;
Xinshun FENG
;
Wujun XUE
;
Ruoyang CHEN
;
Dawei LI
;
Xiaodong YUAN
;
Xiaoming DING
Author Information
1. 西安交通大学第一附属医院肾移植科，西安 710061
- Keywords:
Kidney transplant;
Klebsiella pneumoniae;
Antibiotic
- From:
Chinese Journal of Organ Transplantation
2023;44(5):298-303
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy of ceftazidime/avibactam(CZA)plus aztreonam(ATM)for New Delhi metallo-β-lactamase(NDM)carbapenem-resistant Klebsiella pneumoniae(CRKP)infection after kidney transplantation.Methods:Clinical data are retrospectively reviewed for 11 RT recipients infected with NDM metallo-β-lactamase CRKP admitted into First Affiliated Hospital of Xi 'an Jiaotong University and Affiliated Renji Hospital of Shanghai Jiao Tong University from November 2018 to December 2019.Based upon treatment protocol, they are divided into two groups of ceftazidime/avibactam plus aztreonam(CZA-ATM, 5 cases)and other effective antibiotics(OAA, 6 cases).Age, gender, infection type, drug resistance gene, changes in body temperature and leucocyte count, treatment course and prognosis are summarized.Results:A total of 11 patients with NDM-producing CRKP infection after RT are recruited.There are seven males and four females with an age range of(19~66)(38.9±14.4)years.There are mixed pulmonary and urinary tract infections(3 cases), urinary tract infection(2 cases), pulmonary infection(1 case)and perirenal infection(5 cases).All isolates harbore NDM carbapenemase gene, 5 isolates carry Klebsiella pneumoniae carbapenemase(KPC)gene and 1 isolate contained both imipenemase metallo-β-lactamase(IMP)and verona integron-encoded metallo-β-lactamase(VIM)gene concurrently.Ceftazidime-avibactam plus aztreonam(CZA-ATM)is prescribed in five patients while the remainders receive OAA.No adverse reactions occurred in individuals on CZA-ATM and 2 cases on OAA have adverse reactions with a poor appetite and diarrhea.After 30-day infection, the curative cases of CZA-ATM and OAAs groups reach 4 and 5 respectively.No death occurred in neither groups at Day 30.And 90-day mortality is 0 and 1 respectively.Conclusions:For RT patients infected with NDM-producing CRKP, CZA-ATM combination therapy may be another effective treatment.
